fintopic.
Docs Get the API

FDA rejects ivonescimab lung cancer treatment

4 statements from 4 sources on Nov 15, 2026, 12:00–19:34 UTC
News
Updated
SMMT
Front page

Statements (4)

  1. Bearish

    FDA did not approve Summit Therapeutics' China-developed lung cancer drug ivonescimab due to lack of statistically significant survival benefit.

    investors.comHigh importance
  2. Bearish

    FDA rejects ivonescimab treatment for lung cancer developed by Summit Therapeutics

    statnews.comHigh importance
  3. Bearish

    FDA rejected ivonescimab, a lung cancer treatment from Summit Therapeutics and Akeso

    endpoints.newsHigh importance
  4. Neutral

    FDA issued a Complete Response Letter regarding the BLA for ivonescimab in combination with platinum-containing chemotherapy for Summit Therapeutics

    businesswire.comHigh importance